The Cooper Companies (COO), headquartered in San Ramon, California, develops, manufactures, and markets contact lens wearers. Valued at $16.3 billion by market cap, the company’s products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians.

Shares of this global medical device company have underperformed the broader market over the past year. COO has declined 7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 11.9%. In 2026, COO stock is down marginally, aligning with SPX’s slight fall on a YTD basis.

Cathie Wood Adds 210K Shares to a Rising AI Bet With Upside of 102%

Is GOOG Stock a Buy Amid the Software Selloff?

Broadcom Is ‘Sitting on a Sinking Iceberg.’ Why 1 Analyst Is Warning on AVGO Stock Here.

Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.

Narrowing the focus, COO’s underperformance is also apparent compared to the SPDR S&P Health Care Equipment ETF (XHE). The exchange-traded fund has declined about 6.6% over the past year. However, the stock’s marginal losses on a YTD basis outshine the ETF’s 3.3% decline over the same time frame.

On Dec. 4, 2025, COO shares closed up more than 1% after reporting its Q4 results. Its revenue was $1.07 billion, surpassing analyst estimates of $1.06 billion. The company’s adjusted EPS of $1.15 beat analyst estimates by 3.2%.

For the current fiscal year, ending in October, analysts expect COO’s EPS to grow 9.5% to $4.51 on a diluted basis. The company’s earnings surprise history is impressive. It beat or matched the consensus estimate in each of the last four quarters.

Among the 18 analysts covering COO stock, the consensus is a “Moderate Buy.” That’s based on 10 “Strong Buy” ratings, one “Moderate Buy,” six “Holds,” and one “Strong Sell.”

This configuration is more bullish than a month ago, with nine analysts suggesting a “Strong Sell.”

On Feb. 3, Needham kept a “Buy” rating on COO and lowered the price target to $99, implying a potential upside of 20.8% from current levels.

The mean price target of $90.12 represents a 10% premium to COO’s current price levels. The Street-high price target of $100 suggests an upside potential of 22%.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com